Genzyme’s Mozobil Shows Promise in Chemosensitization
10-Dec-2009 -
Genzyme Corporation announced that a Phase 1/2 trial provided early clinical data suggesting that Mozobil® (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow. The investigational trial, partially supported by Genzyme, ...
acute myeloid leukemia
blood cancer
bone marrow
+6